Do you want to access to this and other private contents?
Log in if you are a subscriber or click here to request service

Palforzia of Aimmune is the first treatment for peanut allergy in the EU

Approved the use of the biological drug, developed by Nestlé health science company

The European Commission has approved the use of Palforzia (defatted powder of Arachis hypogaea L.) for the treatment of peanut allergy in the European Union (EU). Developed by Aimmune Therapeutics, Inc., a Nestlé Health Science Company, Palforzia is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients...

hef - 16007
Bruxelles, Belgio, 01/08/2021 10:53
EFA News - European Food Agency

Similar

HealthNutriplate by Nestlé: sedentary lifestyle to be avoided, starting from childhood

Ideas for improving nutrition and promoting physical activity in children

Too often it is the children themselves who prefer to stay at home, and are more familiar with the TV/Tablet/Mobile-Sofa combination rather than exploring the healthy potential of their body. This does... more

HealthInsomnia. Nestlé Research: a bioactive mixture as an antidote

The discovery was made together with researchers from the National University of Singapore Sleep Center

A study carried out by Nestlé Research, the Research Center based in Lausanne, Switzerland, together with the National University of Singapore Sleep Center, has given rise to an exceptional discovery.... more

HealthWorld Diabetes Day: sweeteners (in certain cases) useful

3.9 million Italians suffer from the disease. The Unione Italiana Food survey suggests remedies

There are 3.9 million, or 6.6% of the population, Italians who suffer from diabetes. In recent years, treatments and awareness of the best ways to manage this disease have made great strides. There are... more